ONTARIO, CA, August 12, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, announces on June 14, 2010 Taylor Capitol, Inc was hired as Investor Relations to replace Mina Mar Marketing Group.
Axxess Pharma, Inc. closed at $0.0125 Thursday, trading 238,800 shares.
Axxess Pharma, Inc. Provides Update Regarding Mina Mar Marketing Group
About Axxess Pharma, Inc.
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2010 -- Hana Biosciences Inc. (OTCBB: HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.
Hana Biosciences Inc. closed at $0.13 Thursday, trading 2,060,629 shares.
Hana Biosciences Reports Second Quarter 2010 Financial Results
About Hana Biosciences, Inc.
Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company's lead product candidate, Marqibo®, potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. Additional information on Hana Biosciences can be found at hanabiosciences.com.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer
-------------------------------------------
Posts
No comments:
Post a Comment